Hexcel HXL
- Market cap
- $6B
- PE
- 40.0×
- 10y median 35.9×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.0×
- EV/EBIT
- 30.4×
- Revenue, 12 months
- $2B
- +5% on a year ago
- Net margin
- 7.8%
- Free cash flow yield
- 4.2%
Hexcel trades at 40.0× trailing earnings, near its ten-year median. Revenue was $2B over the last twelve months, up 5% on a year earlier with a 8% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $419.5M+15% | $457.5M+7% | $472.3M+3% | $500.4M+10% | $456.5M+9% | $473.8M+4% | $456.5M−3% | $489.9M−2% | $456.2M−0% | $491.3M+4% | $501.5M+10% | $529.3M+8% | |
| Cost of revenue | $327.9M+16% | $354.4M+7% | $354.1M+7% | $373.8M+9% | $350M+7% | $355.3M+0% | $354.1M+0% | $378.4M+1% | $356.3M+2% | $370.3M+4% | $366.8M+4% | $391.2M+3% |
| Gross profit | $91.6M+12% | $103.1M+4% | $118.2M−7% | $126.6M+14% | $106.5M+16% | $118.5M+15% | $102.4M−13% | $111.5M−12% | $99.9M−6% | $121M+2% | $134.7M+32% | $138.1M+24% |
| R&D | $13.4M+16% | $12.1M+1% | $15.1M+9% | $14.7M+11% | $13.8M+3% | $13.5M+12% | $13.8M−9% | $14.3M−3% | $14M+1% | $14.3M+6% | $17.8M+29% | $17.3M+21% |
| SG&A | $35.4M+22% | $41.9M+3% | $49M−4% | $39.9M+12% | $39.8M+12% | $47.9M+14% | $43.3M−12% | $43M+8% | $41.1M+3% | $41.6M−13% | $49.4M+14% | $47.2M+10% |
| $43.6M+7% | $47.6M+18% | $52.9M−16% | $71.8M+17% | $52.5M+20% | $8.9M−81% | $44.2M−16% | $30M−58% | $36M−31% | $61.4M+590% | $57.6M+30% | $72.6M+142% | |
| Interest expense | $7.8M−13% | $7.6M−17% | $6.5M−31% | $8.1M−12% | $8.5M+9% | $8.1M+7% | $7.8M+20% | $9.1M+12% | $9.2M+8% | $11.6M+43% | $11.8M+51% | $12M+32% |
| Pre-tax income | $35.8M+13% | −$31.6M | $46.4M−13% | $63.7M+22% | $44M+23% | $800K | $36M−22% | $21.8M−66% | $26.8M−39% | $50.4M+6200% | $45.5M+26% | $60.7M+178% |
| −$700K | −$10.4M | $9.9M−15% | $13.7M+19% | $4.2M | −$5M−52% | $7.1M−28% | $8.3M−39% | $6.2M+48% | $4M | $8.3M+17% | $11.4M+37% | |
| Net income | $38.7M+44% | −$18.2M | $36.5M−15% | $50M+18% | $39.8M+3% | $5.8M | $28.9M−21% | $13.5M−73% | $20.6M−48% | $46.4M+700% | $37.2M+29% | $49.3M+265% |
| $0.45+45% | −$0.22 | $0.43−14% | $0.60+20% | $0.49+9% | $0.07 | $0.35−19% | $0.17−72% | $0.26−47% | $0.60+757% | $0.49+40% | $0.64+277% | |
| 85.6M+1% | 84.6M−1% | 84.8M−1% | 83.2M−3% | 82.1M−4% | 82.1M−3% | 81.7M−4% | 80.6M−3% | 80.3M−2% | 77.3M−6% | 76.7M−6% | 76.5M−5% |
Net income: 60 periods, Q3 FY11 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 17 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20 and Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest Hexcel's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HXLHexcel | $6B | 40.0× | 35.9× | 3.0× | +5% | 7.8% | |
| BCPCBalchem | $5.6B | 34.8× | 41.0× | 5.2× | +9% | 15.1% | |
| EMNEastman Chemical | $7.4B | 16.9× | 13.4× | 0.8× | −5% | 5.0% | |
| CSWCSW Industrials | $4.8B | 40.6× | 34.7× | 4.1× | +28% | 10.3% | |
| ESIElement Solutions | $8.1B | 44.9× | 30.1× | 2.6× | +27% | 5.7% | |
| CBTCabot | $3.8B | 20.8× | 14.4× | 1.0× | −5% | 5.2% | |
| AVNTAvient | $3.8B | 22.2× | 20.2× | 1.1× | +2% | 5.1% | |
| ALBAlbemarle | $11.1B | 347× | 25.7× | 1.9× | +18% | 3.8% | |
| WDFCWD 40 | $2.9B | 32.3× | 39.2× | 4.2× | +10% | 13.2% | |
| FULFuller H B | $2.7B | 13.8× | 22.9× | 0.8× | +1% | 5.6% | |
| IOSPInnospec | $2.4B | 20.1× | 22.3× | 1.3× | +3% | 6.6% | |
| Peer median | $4.3B | 27.3× | 24.3× | 1.6× | +6% | 5.6% |
Investors who own it
Investors we follow who held Hexcel at the end of Jun 30, 2026, from their 13F filings.
- Tom GaynerMarkel Group0.1% of portfolio
More on Hexcel
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #7of 37Chemicals stocks with the highest profit margins
- #3of 14Chemicals stocks with the fastest earnings growth
- #6of 13Chemicals stocks cheapest against their own PE history
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .